Manufacturing

Lonza facility in Walkersville, Maryland (source Google maps)

update

US FDA warns Lonza about Walkersville site

By Gareth Macdonald

The US FDA has warned Lonza about operations at its facility in Walkersville, Maryland, raising concerns about validation and aseptic process simulations.

The UK needs to bridge the skills gap, says ABPI

Jobs

ABPI: fix the manufacturing skills gap now

By Fiona BARRY

The UK biopharma industry is reporting difficulties finding manufacturing workers with the skills to make vaccines, biologics, and advanced therapy medicinal products (ATMP), according to ABPI.

Cipla acquires mAb manufacturer Mabpharm

Cipla acquires mAb manufacturer Mabpharm

By Zachary Brennan

Indian biopharma Cipla is pushing further into the realm of monoclonal antibody manufacturing with its purchase of India-based Mabpharm.

PacificGMP doubles production capacity with GE bioreactor

PacificGMP doubles production capacity with GE bioreactor

By Zachary Brennan

CDMO (contract development and manufacturing organization) PacificGMP has doubled its GMP (good manufacturing practice) production capacity with the addition of a second System 1000 bioreactor platform from GE Healthcare. 

SAFC expands continuous flow capacity in Wisconsin

SAFC expands continuous flow capacity in Wisconsin

By Zachary Brennan

SAFC, the custom manufacturing services business of Sigma-Aldrich, has installed a new commercial-scale continuous flow reactor at its Sheboygan, Wisconsin, facility with capacity to produce up to 150 kg of product per day. 

Survey finds solid base for UK early phase cell therapy manufacturing

Survey finds solid base for early phase cell therapy manufacturing in UK

By Zachary Brennan

The UK manufacturing sector covers all of its bases in terms of the current cell therapy manufacturing requirements and includes “a strong manufacturing base” to bring early phase academic research into the clinic, according to a survey conducted by Cell...

Bristol Myers-Squibb, Samsung extend biologics manufacturing agreement

B-MS, Samsung extend biologics manufacturing agreement

By Zachary Brennan

Bristol-Myers Squibb and Samsung Biologics have expanded their existing agreement in which Samsung will manufacture several unnamed biologics at its Incheon, South Korea manufacturing site. Financial terms of the agreement were not disclosed.